Prerna Mewawalla, MD, a hematologist at Allegheny Health Network, discusses how her approaches to patients with newly diagnosed multiple myeloma have changed recently based on clinical trial outcomes.
Prerna Mewawalla, MD, a hematologist at Allegheny Health Network, discusses how her approaches to patients with newly diagnosed multiple myeloma have changed recently.
She says that for newly diagnosed, transplant-eligible patients, she now uses frontline quadruplet therapies such as Dara-RVd (daratumumab [Darzalex], lenalidomide [Revlimid], bortezomib [Velcade], and dexamethasone) if they are younger or have high-risk disease. Quadruplet therapies with the addition of an anti-CD38 monoclonal antibody have been shown to achieve a deeper response and better progression-free survival (PFS). Based on the DETERMINATION trial (NCT01208662), which showed a median PFS of 18 months, these patients should receive an autologous stem cell transplant after 4 to 6 cycles of quadruplet therapy.
For transplant-ineligible patients, Mewawalla says she uses DRd (daratumumab, lenalidomide, and dexamethasone) based on the MAIA study (NCT02252172). She feels her patients are responding well to this regimen; additionally, it only needs to be given monthly after thesixth 28-day cycle.
According to Mewawalla, results from the SWOG S2209 study (NCT05561387) comparing RVd-lite (modified lenalidomide, bortezomib, and dexamethasone) with DRd could show which regimen is most effective in the transplant-ineligible setting, offering another option for these patients.
TRANSCRIPTION:
0:08 | For a newly diagnosed patient who is transplant eligible, I have started using the quadruple treatments like Dara-RVd in the high-risk population, as well as in my younger patients who we want to achieve a deeper response and have a higher PFS. I'm also transplanting these patients after 4 to 6 cycles based on the DETERMINATION trial and having the PFS of 18 months by doing the transplant.
0:35 | For my newly diagnosed transplant-ineligible patients, I now use DRd upfront in these patients, per the MAIA study. My patients are doing well on it, and they tolerate it extremely well. The [daratumumab] addition has been great. With time, it becomes once a month, so patients like getting it as well.
I am looking forward to data from the SWOG [S2209] study, which is going to compare DRd to RVd-lite and see if that would be another option for these transplant-ineligible patients upfront. That is something I am looking forward [to].
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More